Oncotarget

Research Papers:

Association of the neoadjuvant chemotherapy cycle with survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a propensity-matched analysis

Wang Fangzheng, Jiang Chuner, Ye Zhimin, Sun Quanquan, Liu Tongxin, Xu Min, Wu Peng, Long Bin, Masoto Sakamoto, Wang Yuezhen, Yan Fengqin, Fu Zhenfu and Jiang Yangming _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:94117-94128. https://doi.org/10.18632/oncotarget.21587

Metrics: PDF 918 views  |   HTML 1297 views  |   ?  


Abstract

Wang Fangzheng1,2,3,*, Jiang Chuner4,*, Ye Zhimin1,2, Sun Quanquan1,2, Liu Tongxin1,2, Xu Min5, Wu Peng6, Long Bin7, Masoto Sakamoto3, Wang Yuezhen1,2, Yan Fengqin1,2, Fu Zhenfu1,2 and Jiang Yangming8

1Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang Hangzhou 310022, People’s Republic of China

2Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Hangzhou 310022, People’s Republic of China

3Department of Radiology, Japanese Red Cross Fukui Hospital, Fukui 918-8501, Japan

4Department of Breast Tumor Surgery, Zhejiang Cancer Hospital, Zhejiang Hangzhou 310022, People’s Republic of China

5Department of Physics, Zhejiang Cancer Hospital, Zhejiang Hangzhou 310022, People’s Republic of China

6Department of Pathology, Zhejiang Cancer Hospital, Zhejiang Hangzhou 310022, People’s Republic of China

7Department of Nuclear Medicine, Zhejiang Cancer Hospital, Zhejiang Hangzhou 310022, People’s Republic of China

8Department of Didital Earth, Institute of Remote Sensing and Didital Earth, CAS, Beijing 100101, People’s Republic of China

*These authors have contributed equally to this work

Correspondence to:

Jiang Yangming, email: jym_wm@126.com

Wang Fangzheng, email: wangfz76@126.com

Keywords: nasopharyngeal carcinoma, neoadjuvant chemotherapy, cycle, survival outcomes, prognosis

Received: July 18, 2017     Accepted: September 21, 2017     Published: October 06, 2017

ABSTRACT

Neoadjuvant chemotherapy (NAC) is widely used to treat locoregionally advanced nasopharyngeal carcinoma (NPC). To determine the optimal number of NAC cycles, we assessed the effect of NAC cycle on survival outcomes of locoregionally advanced NPC patients receiving NAC before concurrent chemotherapy and intensity-modulated radiotherapy. Clinical data from 1,188 non-metastatic NPC patients were retrospectively reviewed. All received ≥2 cycles of NAC added to concurrent chemoradiotherapy. Propensity score matching (PSM) was used to identify paired patients according to various covariates. In total, 297 pairs were selected. After a median follow-up time of 57 months (range: 7 to 104 months), the 5-year locoregional relapse-free survival, distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival rates in patients treated with 2 cycles vs. 3 to 4 cycles of NAC were 91.3% vs. 87.2% (P=0.149), 93.3% vs. 88.5% (P=0.043), 88.7% vs. 81.7% (P=0.037), and 94.0% vs. 92.6% (P=0.266), respectively. On multivariate analysis, 2 cycles of NAC were associated with improved DMFS (hazard ratio, 0.499; P=0.038) and PFS (hazard ratio, 0.585; P=0.049). NAC cycle was an independent prognosticator of DMFS and PFS in univariate and multivariate analyses. Thus, 2 cycles of NAC appear sufficient, as additional cycles were not associated with added survival benefit for locoregionally advanced NPC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21587